NCT05955586View on ClinicalTrials.gov

A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

February 9, 2024

Study Completion Date

February 23, 2024

Conditions
Healthy Volunteer
Interventions
DRUG

SPR720

SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.

Trial Locations (1)

85032

Pulmonary Associates, Phoenix

Sponsors

Lead Sponsor

Spero Therapeutics
All Listed Sponsors
lead

Spero Therapeutics

INDUSTRY

NCT05955586 - A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers. | Biotech Hunter | Biotech Hunter